In Vivo Interrogation of Cell-Penetrating Peptide Function: Accumulation in Tumors and the Potential as a Specific PET Probe
Bioconjugate Chemistry · 2025
DOI: 10.1021/acs.bioconjchem.5c00128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Zhan Si und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Cell-Penetrating Peptides, Neoplasms. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Xuhui District Medical Research Projects.
Abstract (Originalsprache)
We aimed to evaluate the biodistribution and specificity of 68Ga-DOTA-TAT and RHO-TAT using MGC-803 and HT-29 tumor cells as well as tumor-xenografted nude mice and to demonstrate its application in positron emission tomography (PET) imaging. The in vitro evaluation of 68Ga-DOTA-TAT was assessed in MGC-803 and HT-29 cell lines, and the in vivo evaluation of 68Ga-DOTA-TAT was also performed in mice bearing MGC-803 or HT-29 tumors, respectively. Fluorescence microscopy was also employed to evaluate the specificity of RHO-TAT in vitro in MGC-803 and HT-29 cells as well as ex vivo in tumor slices of the corresponding tumor models. The in vivo imaging differences between 68Ga-DOTA-TAT and 18F-FDG in MGC-803 and HT-29 tumors were also studied. The biodistribution and micro-PET results demonstrated significant uptake of 68Ga-DOTA-TAT in non-FDG-avid MGC-803 tumors, whereas there was negligible uptake in FDG-avid HT-29 tumors. RHO-TAT showed superior fluorescence microscopy imaging effects in MGC-803 cells and tumor slices but not in HT-29 cells and tumor slices, which were consistent with the in vivo results. 68Ga-DOTA-TAT combined with 18F-FDG can be applied noninvasively in cancers with PET imaging for potential patient selection and stratification. We demonstrated a higher binding of 68Ga-DOTA-TAT and RHO-TAT to MGC-803 cells as well as to non-FDG-avid MGC-803 xenografted tumors and a lower binding to HT-29 cells and FDG-avid xenografted tumors. These results suggest that TAT has the potential to be a ligand for targeting certain tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
- Institute of Nuclear Medicine, Fudan University, Shanghai 200032, China.
- Department of Pharmacy, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
- Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai 200032, China.
- Department of Nuclear Medicine, Shanghai Xuhui Central Hospital, Fudan University, Shanghai 200237, China.
Förderung
- Xuhui District Medical Research Projects
Zitieren
APA
Si, Z., Tian, L., Zhou, H., Lin, J., & Zhou, J. (2025). In Vivo Interrogation of Cell-Penetrating Peptide Function: Accumulation in Tumors and the Potential as a Specific PET Probe. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00128
Vancouver
Si Z, Tian L, Zhou H, Lin J, Zhou J. In Vivo Interrogation of Cell-Penetrating Peptide Function: Accumulation in Tumors and the Potential as a Specific PET Probe. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00128
BibTeX
@article{Si2025,
author = {Si, Zhan and Tian, Lulu and Zhou, Hongxin and Lin, Jiasheng and Zhou, Jun},
title = {In Vivo Interrogation of Cell-Penetrating Peptide Function: Accumulation in Tumors and the Potential as a Specific PET Probe},
journal = {Bioconjugate Chemistry},
year = {2025},
doi = {10.1021/acs.bioconjchem.5c00128}
}
EUVIMED